Viruses as nanomedicine for cancer

References

• VardyJRourkeSTannockIFEvaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future researchJ Clin Oncol200725172455246317485710
   PubMed Web of Science ®Google Scholar
• KimYJooKMJinJNamD-HCancer stem cells and their mechanism of chemo-radiation resistanceInt J Stem Cells20092210911424855529
   PubMedGoogle Scholar
• VardyJTannockICognitive function after chemotherapy in adults with solid tumoursCrit Rev Oncol Hematol200763318320217678745
   PubMed Web of Science ®Google Scholar
• HanahanDWeinberg RobertAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• AmerMHGene therapy for cancer: present status and future perspectiveMol Cell Ther201421119
   Google Scholar
• ChioccaEAOncolytic virusesNat Rev Cancer200221293895012459732
   PubMed Web of Science ®Google Scholar
• BellJMcFaddenGViruses for tumor therapyCell Host Microbe201415326026524629333
   PubMed Web of Science ®Google Scholar
• KaufmanHLKohlhappFJZlozaAOncolytic viruses: a new class of immunotherapy drugsNat Rev Drug Discov201514964266226323545
   PubMed Web of Science ®Google Scholar
• ChioccaEARabkinSDOncolytic viruses and their application to cancer immunotherapyCancer Immunol Res20142429530024764576
   PubMed Web of Science ®Google Scholar
• PatelMRKratzkeRAOncolytic virus therapy for cancer: the first wave of translational clinical trialsTransl Res2013161435536423313629
   PubMed Web of Science ®Google Scholar
• GuoZSBartlettDLOncolytic viruses as platform for multimodal cancer therapeutics: a promising landCancer Gene Ther201421726126325034971
   PubMedGoogle Scholar
• KirnDHThorneSHTargeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancerNat Rev Cancer200991647119104515
   PubMed Web of Science ®Google Scholar
• JeffersonACadetVEHielscherAThe mechanisms of genetically modified vaccinia viruses for the treatment of cancerCrit Rev Oncol Hematol201595340741625900073
   PubMed Web of Science ®Google Scholar
• GuseKCerulloVHemminkiAOncolytic vaccinia virus for the treatment of cancerExpert Opin Biol Ther201111559560821338330
   PubMed Web of Science ®Google Scholar
• YouZFischerDCTongXHasenburgAAguilar-CordovaEKiebackDGCoxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expressionCancer Gene Ther20018316817511332987
   PubMedGoogle Scholar
• WangHLiZYLiuYDesmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14Nat Med20111719610421151137
   PubMed Web of Science ®Google Scholar
• ShafrenDRDorahyDJInghamRABurnsGFBarryRDCoxsacki-evirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entryJ Virol1997716473647439151867
   PubMed Web of Science ®Google Scholar
• FarassatiFYangADLeePWOncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1Nat Cell Biol20013874575011483960
   PubMed Web of Science ®Google Scholar
• DörigREMarcilAChopraARichardsonCDThe human CD46 molecule is a receptor for measles virus (Edmonston strain)Cell19937522953058402913
   PubMed Web of Science ®Google Scholar
• MansourMPalesePZamarinDOncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cellsJ Virol201185126015602321471241
   PubMed Web of Science ®Google Scholar
• SchmidtFIBleckCKMercerJPoxvirus host cell entryCurr Opin Virol201221202722440962
   PubMedGoogle Scholar
• MerrillMKBernhardtGSampsonJHWikstrandCJBignerDDGromeierMPoliovirus receptor CD155-targeted oncolysis of gliomaNeuro Oncol20046320821715279713
   PubMed Web of Science ®Google Scholar
• DegosLLinchDCLöwenbergBTextbook of Malignant HaematologyCRC PressLondon1999
   Google Scholar
• HarbourJWDeanDCRb function in cell-cycle regulation and apoptosisNat Cell Biol200024E65E6710783254
   PubMedGoogle Scholar
• MartinezJGeorgoffIMartinezJLevineAJCellular localization and cell cycle regulation by a temperature-sensitive p53 proteinGenes Dev1991521511591995413
   PubMedGoogle Scholar
• CollinsKJacksTPavletichNPThe cell cycle and cancerProc Natl Acad Sci U S A1997947277627789096291
   PubMed Web of Science ®Google Scholar
• TakaiYSasakiTMatozakiTSmall GTP-binding proteinsPhysiol Rev200181115320811152757
   PubMed Web of Science ®Google Scholar
• KimMWilliamsonCTPrudhommeJThe viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene statusOncogene201029273990399620473328
   PubMed Web of Science ®Google Scholar
• IlkowCSMarguerieMBatenchukCReciprocal cellular crosstalk within the tumor microenvironment promotes oncolytic virus activityNat Med201521553053625894825
   PubMed Web of Science ®Google Scholar
• PrestwichRJHarringtonKJPandhaHSVileRGMelcherAAErringtonFOncolytic viruses: a novel form of immunotherapyExpert Rev Anticancer Ther20088101581158818925850
   PubMed Web of Science ®Google Scholar
• GajewskiTFSchreiberHFuYXInnate and adaptive immune cells in the tumor microenvironmentNat Immunol201314101014102224048123
   PubMed Web of Science ®Google Scholar
• Alvarez-BreckenridgeCKaurBChioccaEAPharmacologic and chemical adjuvants in tumor virotherapyChem Rev200910973125314019462957
   PubMedGoogle Scholar
• RoulstoneVKhanKPandhaHSPhase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumorsClin Cancer Res20152161305131225424857
   PubMedGoogle Scholar
• AdairRARoulstoneVScottKJCell carriage, delivery, and selective replication of an oncolytic virus in tumor in patientsSci Transl Med20124138138ra177
   Web of Science ®Google Scholar
• IlettEJPrestwichRJKottkeTDendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunityGene Ther200916568969919282847
   PubMed Web of Science ®Google Scholar
• PowerATWangJFallsTJCarrier cell-based delivery of an oncolytic virus circumvents antiviral immunityMol Ther200715112313017164783
   PubMed Web of Science ®Google Scholar
• LemayCGRintoulJLKusAHarnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccineMol Ther20122091791179922760544
   PubMed Web of Science ®Google Scholar
• YuanZYZhangLLiSQianXZGuanZZSafety of an E1B deleted adenovirus administered intratumorally to patients with cancerAi Zheng2003223310313 Chinese12654194
   PubMedGoogle Scholar
• FieldsBNKnipeDMHowleyPMFields Virology5th edPhiladelphiaWolters Kluwer Health/Lippincott Williams & Wilkins2007
   Google Scholar
• PolandGAGrabensteinJDNeffJMThe US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation programVaccine20052317–182078208115755574
   PubMed Web of Science ®Google Scholar
• PuhlmannMBrownCKGnantMVaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutantCancer Gene Ther200071667310678358
   PubMed Web of Science ®Google Scholar
• LockerJKKuehnASchleichSEntry of the two infectious forms of vaccinia virus at the plasma membane is signaling-dependent for the IMV but not the EEVMol Biol Cell20001172497251110888684
   PubMed Web of Science ®Google Scholar
• ChungC-SHsiaoJ-CChangY-SChangWA27L protein mediates vaccinia virus interaction with cell surface heparan sulfateJ Virol1998722157715859445060
   PubMed Web of Science ®Google Scholar
• SenkevichTGOjedaSTownsleyANelsonGEMossBPoxvirus multiprotein entry-fusion complexProc Natl Acad Sci U S A200510251185721857716339313
   PubMedGoogle Scholar
• TownsleyACMossBTwo distinct low-pH steps promote entry of vaccinia virusJ Virol200781168613862017553884
   PubMedGoogle Scholar
• TolonenNDoglioLSchleichSLockerJKVaccinia virus DNA replication occurs in endoplasmic reticulum-enclosed cytoplasmic mini-nucleiMol Biol Cell20011272031204611452001
   PubMed Web of Science ®Google Scholar
• Di PaoloNCMiaoEAIwakuraYVirus binding to a plasma membrane receptor triggers interleukin-1α-mediated proinflammatory macrophage response in vivoImmunity200931111012119576795
   PubMedGoogle Scholar
• ParatoKABreitbachCJLe BoeufFThe oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancersMol Ther201220474975822186794
   PubMed Web of Science ®Google Scholar
• EhrigKChenNGStritzkerJVaccinia virus-mediated expression of transcription factor Klf4 enhances oncolytic virotherapy of colorectal cancerJ Hum Virol Retrovirol20142400051
   Google Scholar
• YuFWangXGuoZSBartlettDLGottschalkSMSongXTT-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapyMol Ther201422110211124135899
   PubMed Web of Science ®Google Scholar
• BuckelLAdvaniSJFrentzenACombination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endotheliumInt J Cancer2013133122989299923729266
   PubMed Web of Science ®Google Scholar
• HuangTWangHChenNGFrentzenAMinevBSzalayAAExpression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapyMol Ther – Oncol2015215003
   Google Scholar
• GholamiSChenCHLouEVaccinia virus GLV-1h153 is effective in treating and preventing metastatic triple-negative breast cancerAnn Surg2012256343744522868370
   PubMed Web of Science ®Google Scholar
• GholamiSChenCHLouEVaccinia virus GLV-1h153 in combination with 131I shows increased efficiency in treating triple-negative breast cancerFASEB J201428267668224186964
   PubMed Web of Science ®Google Scholar
• GholamiSChenCHBelinLJVaccinia virus GLV-1h153 is a novel agent for detection and effective local control of positive surgical margins for breast cancerBreast Cancer Res2013152R2623506710
   PubMed Web of Science ®Google Scholar
• MansfieldDCKyulaJNRosenfelderNOncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancerGene Ther201623435736826814609
   PubMed Web of Science ®Google Scholar
• GentschevIMullerMAdelfingerMEfficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68PLoS One201167e2206921779374
   PubMedGoogle Scholar
• AdelfingerMBesslerSFrentzenAPreclinical testing oncolytic vaccinia virus strain GLV-5b451 expressing an anti-VEGF single-chain antibody for canine cancer therapyViruses2015774075409226205404
   PubMedGoogle Scholar
• KimJHOhJYParkBHSystemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSFMol Ther200614336137016905462
   PubMed Web of Science ®Google Scholar
• BreitbachCJBurkeJJonkerDIntravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humansNature201147773629910221886163
   PubMed Web of Science ®Google Scholar
• YooSYBangSYJeongSNKangDHHeoJA cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancerOncotarget2016713164791648926918725
   PubMedGoogle Scholar
• RojasJJSampathPHouWThorneSHDefining effective combinations of immune checkpoint blockade and oncolytic virotherapyClin Cancer Res201521245543555126187615
   PubMed Web of Science ®Google Scholar
• FendLRemy-ZillerCFoloppeJOncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironmentOncoimmunology201652e108041427057460
   PubMedGoogle Scholar
• Le BoeufFDialloJSMcCartJASynergistic interaction between oncolytic viruses augments tumor killingMol Ther201018588889520234341
   PubMed Web of Science ®Google Scholar
• ParviainenSAhonenMDiaconuIGMCSF-armed vaccinia virus induces an antitumor immune responseInt J Cancer201513651065107225042001
   PubMedGoogle Scholar
• BurdickKHHawkWAVitiligo in a case of vaccinia virus-treated melanomaCancer196417670871214172076
   PubMedGoogle Scholar
• WallackMKSteplewskiZKoprowskiHA new approach in specific, active immunotherapyCancer1977392560564189895
   PubMed Web of Science ®Google Scholar
• ArakawaSJrHamamiGUmezuKKamidonoSIshigamiJArakawaSClinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinomaJ Cancer Res Clin Oncol1987113195983818784
   PubMed Web of Science ®Google Scholar
• MastrangeloMJMaguireHCEisenlohrLCIntratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanomaCancer Gene Ther19996540942210505851
   PubMed Web of Science ®Google Scholar
• GomellaLGMastrangeloMJMcCuePAMaguireHCMulhollandSGLattimeECPhase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancerJ Urol200116641291129511547060
   PubMed Web of Science ®Google Scholar
• AndtbackaRHKaufmanHLCollichioFTalimogene laherparepvec improves durable response rate in patients with advanced melanomaJ Clin Oncol201533252780278826014293
   PubMed Web of Science ®Google Scholar
• GarberKChina approves world’s first oncolytic virus therapy for cancer treatmentJ Natl Cancer Inst200698529830016507823
   PubMedGoogle Scholar
• LiuTCGalanisEKirnDClinical trial results with oncolytic virotherapy: a century of promise, a decade of progressNat Clin Pract Oncol20074210111717259931
   PubMedGoogle Scholar
• JebarAHErrington-MaisFVileRGSelbyPJMelcherAAGriffinSProgress in clinical oncolytic virus-based therapy for hepatocellular carcinomaJ Gen Virol201596pt 71533155025711964
   PubMed Web of Science ®Google Scholar
• GENELUX [webpage on the Internet]. Clinical Trails Available from: http://www.genelux.com/clinical-trials/Accessed August 23, 2016
   Google Scholar
• ParkB-HHwangTLiuT-CUse of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trialLancet Oncol20089653354218495536
   PubMed Web of Science ®Google Scholar
• LiuTCHwangTParkBHBellJKirnDHThe targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinomaMol Ther20081691637164218628758
   PubMed Web of Science ®Google Scholar
• HeoJBreitbachCJMoonASequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacyMol Ther20111961170117921427706
   PubMed Web of Science ®Google Scholar
• HeoJReidTRuoLRandomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNat Med201319332933623396206
   PubMed Web of Science ®Google Scholar
• ZehHJDowns-CannerSMcCartJAFirst-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activityMol Ther201523120221425292189
   PubMed Web of Science ®Google Scholar
• AghiMMartuzaRLOncolytic viral therapies – the clinical experienceOncogene200524527802781616299539
   PubMed Web of Science ®Google Scholar
• EvginLAcunaSATanese de SouzaCComplement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaquesMol Ther20152361066107625807289
   PubMed Web of Science ®Google Scholar
• ThorneSHNegrinRSContagCHSynergistic antitumor effects of immune cell-viral biotherapyScience200631157681780178416556847
   PubMed Web of Science ®Google Scholar
• WillmonCHarringtonKKottkeTPrestwichRMelcherAVileRCell carriers for oncolytic viruses: Fed Ex for cancer therapyMol Ther200917101667167619690519
   PubMed Web of Science ®Google Scholar
• ParkSHBreitbachCJLeeJPhase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancerMol Ther20152391532154026073886
   PubMed Web of Science ®Google Scholar
• WilkinsonMJSmithHGPencavelTDIsolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcomaInt J Cancer201613961414142227116656
   PubMedGoogle Scholar
• SimpsonGRHorvathAAnnelsNECombination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancerBr J Cancer2012106349650722240799
   PubMed Web of Science ®Google Scholar
• LucasTBenihoudKVigantFHexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancerPLoS One2015102e011725425692292
   PubMedGoogle Scholar
• PoppersJMulveyMKhooDMohrIInhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 proteinJ Virol20007423112151122111070019
   PubMed Web of Science ®Google Scholar
• MiyamotoSInoueHNakamuraTCoxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinomaCancer Res201272102609262122461509
   PubMed Web of Science ®Google Scholar
• LeberMFBossowSLeonardVHMicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropismMol Ther20111961097110621468006
   PubMed Web of Science ®Google Scholar
• JankeMPeetersBde LeeuwORecombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapyGene Ther200714231639164917914407
   PubMed Web of Science ®Google Scholar